Business Description
NeuroPace Inc
NAICS : 423450
SIC : 5047
ISIN : US6412881053
Total Employee Number:
220Description
NeuroPace Inc is a medical device company focused on transforming the lives of people living with epilepsy by reducing or eliminating the occurrence of seizures. The company offers the RNS System, a brain-responsive neuromodulation system that continuously monitors and analyzes the brain's electrical activity and delivers personalized, real-time electrical pulses at the seizure source to prevent seizures. The RNS System includes the RNS neurostimulator, cortical strip leads, depth leads, a Patient Remote Monitor, and other implantable and non-implantable accessories used during implant procedures. The company also provides the Physician Tablet, Patient Data Management System, and the nSight Platform to facilitate ongoing patient monitoring and support clinicians in managing patient care.
Financial Strength
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.77 | |||||
Equity-to-Asset | 0.15 | |||||
Debt-to-Equity | 4.88 | |||||
Debt-to-EBITDA | -5.53 | |||||
Piotroski F-Score | 5/9 | |||||
Altman Z-Score | -2.43 | |||||
Beneish M-Score | -0.37 | |||||
WACC vs ROIC | ||||||
Growth Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 18.2 | |||||
3-Year EBITDA Growth Rate | 37.2 | |||||
3-Year EPS without NRI Growth Rate | 29.8 | |||||
3-Year FCF Growth Rate | 39 | |||||
3-Year Book Growth Rate | -25.8 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 52.41 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 16.06 |
Momentum Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 59.69 | |||||
9-Day RSI | 59.13 | |||||
14-Day RSI | 57.25 | |||||
3-1 Month Momentum % | 10.17 | |||||
6-1 Month Momentum % | -6.1 | |||||
12-1 Month Momentum % | 54.47 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 5.38 | |||||
Quick Ratio | 4.35 | |||||
Cash Ratio | 3.34 | |||||
Days Inventory | 275.9 | |||||
Days Sales Outstanding | 53.83 | |||||
Days Payable | 67.87 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -10.3 | |||||
Shareholder Yield % | 0.53 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 78.29 | |||||
Operating Margin % | -16.84 | |||||
Net Margin % | -21.67 | |||||
EBITDA Margin % | -12.8 | |||||
FCF Margin % | -9.88 | |||||
OCF Margin % | -9.47 | |||||
ROE % | -112.66 | |||||
ROA % | -20.42 | |||||
ROIC % | -55.24 | |||||
3-Year ROIIC % | 1347.44 | |||||
ROC (Joel Greenblatt) % | -49.92 | |||||
ROCE % | -16.65 | |||||
Moat Score | 4 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 5.73 | |||||
PB Ratio | 39.79 | |||||
Price-to-Tangible-Book | 39.79 | |||||
EV-to-EBIT | -40.69 | |||||
EV-to-EBITDA | -47.08 | |||||
EV-to-Revenue | 6.03 | |||||
EV-to-Forward-Revenue | 6 | |||||
EV-to-FCF | -60.98 | |||||
Price-to-GF-Value | 1.5 | |||||
| Price-to-Net-Current-Asset-Value | 244.43 | |||||
Earnings Yield (Greenblatt) % | -2.46 | |||||
FCF Yield % | -1.69 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:NPCE
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
NeuroPace Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 99.53 | ||
| EPS (TTM) ($) | -0.65 | ||
| Beta | 1.0494 | ||
| 3-Year Sharpe Ratio | 0.76 | ||
| 3-Year Sortino Ratio | 1.97 | ||
| Volatility % | 78.37 | ||
| 14-Day RSI | 57.25 | ||
| 14-Day ATR ($) | 0.83801 | ||
| 20-Day SMA ($) | 16.166 | ||
| 12-1 Month Momentum % | 54.47 | ||
| 52-Week Range ($) | 7.5625 - 19.6 | ||
| Shares Outstanding (Mil) | 34.09 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
NeuroPace Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
NeuroPace Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-11-04 16:30 | In 117 days | ||
| Third quarter earnings results for 2026 | 2026-11-04 | In 116 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-12 16:30 | In 33 days | ||
| Second quarter earnings results for 2026 | 2026-08-12 | In 32 days | ||
| General meeting for 2026 | 2026-06-05 10:30 | 16.32 (+2.32%) | ||
| First quarter earnings conference call for 2026 | 2026-05-12 16:30 | 15.67 (-14.60%) | ||
| First quarter earnings results for 2026 | 2026-05-12 | 15.67 (-14.60%) | ||
| 25th Annual Needham Virtual Healthcare Conference | 2026-04-14 13:30 | 14.88 (+3.98%) | ||
| Leerink Global Healthcare Conference | 2026-03-11 20:40 | 14.22 (+2.67%) | ||
| Fourth quarter earnings conference call for 2025 | 2026-03-03 16:30 | 14.15 (-0.35%) |
Show
Entries
NeuroPace Inc Frequently Asked Questions
What is NeuroPace Inc(NPCE)'s stock price today?
The current price of NPCE is $17.11. The 52 week high of NPCE is $19.60 and 52 week low is $7.56.
When is next earnings date of NeuroPace Inc(NPCE)?
The next earnings date of NeuroPace Inc(NPCE) is 2026-08-12 Est..
Does NeuroPace Inc(NPCE) pay dividends? If so, how much?
NeuroPace Inc(NPCE) does not pay dividend.
Guru Commentaries on NAS:NPCE
No articles.
Press Release
Articles on NeuroPace Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers